- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy | Clinical
FDA Grants RMAT and Fast Track Designations to Allogeneic CAR T-Cell Therapy for B-NHL
November 30, 2022
The allogeneic CAR T-cell therapy CB-010 received regenerative medicine advanced therapy and Fast Track designations for the treatment of patients with B-cell non-Hodgkin lymphoma.
UCART19 Shows Promising Safety/Efficacy in Adult Patients With B-Cell ALL
November 30, 2022
Findings from the phase 1 CALM study evaluating the allogeneic genome-edited anti-CD19 chimeric antigen receptor T-cell product UCART19 show it can be safely used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALL
November 22, 2022
In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.
Investigating Donor-Derived CAR T Cells in R/R Large B-Cell Lymphoma
November 22, 2022
In an interview with Targeted Oncology, Michael T. Tees, MD, discussed the donor-derived CAR T-cell product, ALLO-501A, and research supporting the agent.
Overview of Allogeneic CAR T-Cell Therapy Trials for ALL, AML, and NHL
November 08, 2022
Nitin Jain, MD, discusses clinical trials investigating allogeneic chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia and other hematologic malignancies.
Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell Therapy
November 07, 2022
Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.
Tisagenlecleucel Shows Promise in Pediatric Patients with ALL
November 03, 2022
The CAR T-cell therapy tisagenlecleucel showed promising anti-tumor activity in pediatric patients with acute lymphoblastic leukemia.
Allogeneic CAR T-Cell Therapy May Provide Alternate Options in ALL
October 24, 2022
In an interview with Targeted Oncology, Nitin Jain, MD, further discussed the ongoing research of allogeneic chimeric antigen receptor T cells as treatment for patients with ALL. He also notes what future research must examine to further the field.
Identifying Patients With R/R MM Who Should Receive CAR T-Cell Therapy
October 18, 2022
Adam Cohen, MD, discusses when patients should receive chimeric antigen receptor T-cell therapies for relapsed/refractory multiple myeloma.
Administering CAR T-Cell Therapy in the Community Setting
October 17, 2022
Peter A. McSweeney, MD, discusses the challenges that come with administering chimeric antigen receptor T-cell therapy. He also explains how CAR T cells entering the second-line may change the ways community practices choose treatments for their patients.